PRESS RELEASE

SALT LAKE CITY--(BUSINESS WIRE)--#claimguard--Burgex Mining Consultants – a leading provider in mining claim staking services – is now offering a premium service to alleviate claim holders’ angst around the Bureau of Land Management’s annual filing deadline. For many individual claim holders and mining companies alike, the BLM’s September 1st deadline for filing and renewing mineral claims has caused severe headache and frustration. A missed filing has even cost some companies hundreds of thousands to millions of dollars due to having to re-stake and re-file the lost claims. Some lost claims may not be recovered at all. The BLM has no grace period, even for long-term holders, when the deadline and filing requirements have not been met.

LEXINGTON, Ky.--(BUSINESS WIRE)--Intralink-Spine, Inc. (ILS) announces the expansion of clinical trials for their patented injectable medical device, Réjuve ®, intended in Australia for the treatment of low back pain. “We’re pleased that Dr. Yu and Dr. Green have joined Dr. Rosenberg to participate in the GEM-SE clinical study for low back pain,” says Lyle Hawkins, CEO of Intralink-Spine, Inc.

DALLAS--(BUSINESS WIRE)--According to World Economic Forum, at the current rate, it will take 140 years to achieve gender equality in top leadership positions1 and 99.5 years to have a gender equal world.2 As workplaces across the globe gradually reopen amidst COVID-19 concerns, the fight for women’s empowerment in the public and private sectors must continue.“At a time when COVID-19 crisis has exacerbated women’s vulnerabilities and gender inequality, resulting in a ‘shadow pandemic,’

- QINLOCK is the First Approved Tyrosine Kinase Inhibitor Designed Specifically for GIST Regardless of Patients’ Mutational Status -- QINLOCK Approved via the U.S. FDA’s Project Orbis Initiative -WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the Australian Therapeutic Goods Administration (TGA) has approved QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. The QINLOCK Marketing Authorisation Application was approved by the TGA under Project Orbis, an initiative of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence designed to provide a framework for concurrent submission and review of oncology products among international partners. QINLOCK is also approved by the U.S. FDA for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib, and authorized by Health Canada for the treatment of adult patients with advanced GIST who have received prior treatment with imatinib, sunitinib, and regorafenib.